125 related articles for article (PubMed ID: 18069274)
41. Multiple myeloma.
Raab MS; Podar K; Breitkreutz I; Richardson PG; Anderson KC
Lancet; 2009 Jul; 374(9686):324-39. PubMed ID: 19541364
[TBL] [Abstract][Full Text] [Related]
42. Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial.
Pönisch W; Rozanski M; Goldschmidt H; Hoffmann FA; Boldt T; Schwarzer A; Ritter U; Rohrberg R; Schwalbe E; Uhlig J; Zehrfeld T; Schirmer V; Haas A; Kreibich U; Niederwieser D;
Br J Haematol; 2008 Oct; 143(2):191-200. PubMed ID: 18752593
[TBL] [Abstract][Full Text] [Related]
43. Overview of drug therapy for multiple myeloma.
Saunders G
J Oncol Pharm Pract; 2005 Sep; 11(3):83-100. PubMed ID: 16390597
[TBL] [Abstract][Full Text] [Related]
44. ASH evidence-based guidelines: what is the role of maintenance therapy in the treatment of multiple myeloma?
Ghobrial IM; Stewart AK
Hematology Am Soc Hematol Educ Program; 2009; ():587-9. PubMed ID: 20008243
[TBL] [Abstract][Full Text] [Related]
45. Efficacy of thalidomide therapy for extramedullary relapse of myeloma following allogeneic transplantation.
Biagi JJ; Mileshkin L; Grigg AP; Westerman DW; Prince HM
Bone Marrow Transplant; 2001 Dec; 28(12):1145-50. PubMed ID: 11803357
[TBL] [Abstract][Full Text] [Related]
46. Autologous peripheral blood stem cell transplantation for multiple myeloma: a report of 259 cases from the Spanish Registry. Spanish Registry for Transplant in MM (Grupo Español de Trasplante Hematopoyético-GETH) and PETHEMA.
Alegre A; Díaz-Mediavilla J; San-Miguel J; Martínez R; García Laraña J; Sureda A; Lahuerta JJ; Morales D; Bladé J; Caballero D; De la Rubia J; Escudero A; Díez-Martín JL; Hernández-Navarro F; Rifón J; Odriozola J; Brunet S; De la Serna J; Besalduch J; Vidal MJ; Solano C; Leon A; Sánchez JJ; Martínez-Chamorro C; Fernández-Rañada JM
Bone Marrow Transplant; 1998 Jan; 21(2):133-40. PubMed ID: 9489629
[TBL] [Abstract][Full Text] [Related]
47. Thalidomide, dexamethasone, Doxil and Velcade (ThaDD-V) followed by consolidation/maintenance therapy in patients with relapsed-refractory multiple myeloma.
Offidani M; Corvatta L; Polloni C; Gentili S; Mele A; Rizzi R; Catarini M; Caraffa P; Samori A; Blasi N; Ferranti M; Malerba L; Brunori M; Leoni P
Ann Hematol; 2011 Dec; 90(12):1449-56. PubMed ID: 21437586
[TBL] [Abstract][Full Text] [Related]
48. Interferon in metastatic renal cell carcinoma.
Fosså SD
Semin Oncol; 2000 Apr; 27(2):187-93. PubMed ID: 10768597
[TBL] [Abstract][Full Text] [Related]
49. Understanding novel therapeutic agents for multiple myeloma.
Tariman JD
Clin J Oncol Nurs; 2003; 7(5):521-8. PubMed ID: 14603548
[TBL] [Abstract][Full Text] [Related]
50. [The polychemotherapy of patients with multiple myeloma].
Abdulkadyrov KM; Bessmel'tsev SS
Vopr Onkol; 1992; 38(3):345-51. PubMed ID: 1300725
[TBL] [Abstract][Full Text] [Related]
51. Low-dose thalidomide for multiple myeloma: interim analysis of a compassionate use program.
Steurer M; Spizzo G; Mitterer M; Gastl G
Onkologie; 2004 Apr; 27(2):150-4. PubMed ID: 15138347
[TBL] [Abstract][Full Text] [Related]
52. The role of interferon-alpha in the management of myelomatosis.
Avvisati G; Mandelli F
Hematol Oncol Clin North Am; 1992 Apr; 6(2):395-405. PubMed ID: 1582981
[TBL] [Abstract][Full Text] [Related]
53. Patient preferences for interferon alfa in multiple myeloma.
Ludwig H; Fritz E; Neuda J; Durie BG
J Clin Oncol; 1997 Apr; 15(4):1672-9. PubMed ID: 9193368
[TBL] [Abstract][Full Text] [Related]
54. How does interferon-alpha exert its antitumour activity in multiple myeloma?
Grandér D
Acta Oncol; 2000; 39(7):801-5. PubMed ID: 11145436
[TBL] [Abstract][Full Text] [Related]
55. Interferon: a new strategy in the treatment of multiple myeloma.
Mandelli F; Avvisati G; Petrucci MT
Eur J Haematol Suppl; 1989; 51():129-34. PubMed ID: 2483380
[No Abstract] [Full Text] [Related]
56. Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients.
Myeloma Trialists' Collaborative Group
Br J Haematol; 2001 Jun; 113(4):1020-34. PubMed ID: 11442498
[TBL] [Abstract][Full Text] [Related]
57. Effects of native human leukocyte interferon-alpha and recombinant human interferon-alpha on P3-X63-Ag8.653 mouse myeloma cell growth.
Plesnicar A; Vidmar G; Stabuc B; Kores Plesnicar B
J Int Med Res; 2009; 37(5):1570-6. PubMed ID: 19930865
[TBL] [Abstract][Full Text] [Related]
58. Therapy with interferons in blood diseases.
Polli E; Cortelezzi A
Acta Haematol; 1987; 78 Suppl 1():64-9. PubMed ID: 2449025
[TBL] [Abstract][Full Text] [Related]
59. Interferon in the Treatment of Multiple Myeloma.
Shustik C
Cancer Control; 1998 May; 5(3):226-234. PubMed ID: 10761056
[TBL] [Abstract][Full Text] [Related]
60. Interferon-alpha as maintenance therapy in patients with multiple myeloma.
Yalcin B; Dogan M; Buyukcelik A; Doruk H; Tek I; Demirkazik A
Ann Oncol; 2005 Dec; 16(12):1981. PubMed ID: 16081472
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
